Novartis Scores Another CSU Success With Remibrutinib
Oral BTK Inhibitor Controls Itching And Hives In Phase IIb
Executive Summary
The Swiss group believes that remibrutinib, as well as its investigational IgE antibody ligelizumab, will complement standard of care Xolair and help it build a strong franchise for chronic spontaneous urticaria.
You may also be interested in...
Novartis Confident About Transforming CSU Landscape
With its BTK inhibitor remibrutinib advancing through Phase III trials and work getting started on a CAR-T therapy for lupus, Novartis’s Marie-France Tschudin tells Scrip that the Swiss major’s immunology pipeline is in a healthy state.
Drug Price Reform Concerns Novartis Pharma President Tschudin
"We are definitely worried," Tschudin said about some US drug price reform proposals. She also spoke with Scrip about competitive rebating and new growth opportunities for anchor brands.
Sanofi's Rilzabrutinib Fails At First Hurdle In Pemphigus Study
Analysts who felt Sanofi paid way over the odds when splashing out $3.7bn to buy Principia last year will be feeling justified in that stance after one of the oral BTK inhibitors acquired, rilzabrutinib, proved to be no more effective than placebo in a Phase III trial.